Back to first-pass browser

First-pass extracted concept

NF-κβ suppression modalities

Candidate: concept label1 source documents9 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

factors regulating NF-κβ, microbes

Extracted Explainers

What the tool is doing

This concept groups the intervention classes the review says can suppress NF-κβ in IBD. It is useful as a review-level label rather than a single tool.

Source 1DOIPubMed

What problem it solves

It summarizes the therapeutic design space discussed in the abstract for reducing NF-κβ-driven inflammation.

Source 1DOIPubMed

What it does not solve

It does not identify a specific implementable reagent or protocol from the abstract.

Source 1DOIPubMed

Alternatives

The abstract itself breaks this concept into ASOs, siRNA, factors regulating NF-κβ, and microbes.

Source 1DOIPubMed

Evidence Snippets

Suppression of NF-κβ can be achieved through many modalities including anti-sense oligonucleotides (ASOs), siRNA (small interfering RNA), factors regulating NF-κβ, and microbes.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1disease associationsupports2018Source 1DOIPubMed

Dysregulation of the NF-κβ pathway and its regulators contributes to uncontrolled inflammation and altered immunity in IBD.

Claim 2disease biomarker or statesupports2018Source 1DOIPubMed

Proinflammatory cytokines regulated through NF-κβ are increased in both Crohn disease and ulcerative colitis.

Claim 3genetic associationsupports2018Source 1DOIPubMed

Genes known to activate NF-κβ, including NOD2 and IL-23, are associated with IBD.

Claim 4microbiome modulationsupports2018Source 1DOIPubMed

Gut commensals can exert anti-inflammatory activities toward NF-κβ and may help attenuate inflammation associated with microbial dysbiosis in IBD.

Claim 5pathogenic consequencesupports2018Source 1DOIPubMed

Failure to terminate or downregulate NF-κβ signaling results in chronic inflammation in IBD.

Claim 6pathway rolesupports2018Source 1DOIPubMed

NF-κβ plays a major role in gut homeostasis and contributes to balanced immune homeostasis.

Claim 7pediatric associationsupports2018Source 1DOIPubMed

NOD-2 and A20 are strongly associated with pediatric IBD.

Claim 8regulatory failuresupports2018Source 1DOIPubMed

Inhibitors of NF-κβ such as A20 and TOLLIP are affected in IBD, resulting in failed inflammation suppression or regulation.

Claim 9therapeutic strategysupports2018Source 1DOIPubMed

Suppression of NF-κβ can be achieved through modalities including ASOs, siRNA, factors regulating NF-κβ, and microbes.